Citations (74)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Thomas E. Hutson. (2007) Targeted Therapy for Renal Cell Carcinoma: A New Treatment Paradigm. Baylor University Medical Center Proceedings 20:3, pages 244-248.
Read now
Read now
Onur Boyman, Charles D Surh & Jonathan Sprent. (2006) Potential use of IL-2/anti-IL-2 antibody immune complexes for the treatment of cancer and autoimmune disease. Expert Opinion on Biological Therapy 6:12, pages 1323-1331.
Read now
Read now
Philip E Shaheen & Ronald M Bukowski. (2005) Emerging drugs for renal cell carcinoma. Expert Opinion on Emerging Drugs 10:4, pages 773-795.
Read now
Read now
Francis J Dumont. (2005) Interleukin-2 family cytokines: potential for therapeutic immmunoregulation. Expert Opinion on Therapeutic Patents 15:5, pages 521-554.
Read now
Read now
Articles from other publishers (70)
Luke M. Tomasovic, Kathy Liu, Derek VanDyke, Charina S. Fabilane & Jamie B. Spangler. (2023) Molecular Engineering of Interleukin-2 for Enhanced Therapeutic Activity in Autoimmune Diseases. BioDrugs.
Crossref
Crossref
Parisa Shiri Aghbash, Reyhaneh Rasizadeh, Amir Hossein Yari, Shiva Lahouti, Habib MotieGhader, Javid Sadri Nahand, Taher Entezari-Maleki & Hossein Bannazadeh Baghi. (2023) Interleukin-2 and Oncolytic Virotherapy: A New Perspective in Cancer Therapy. Anti-Cancer Agents in Medicinal Chemistry 23:18, pages 2008-2026.
Crossref
Crossref
Alison McFarlane, Elizabeth Pohler & Ignacio Moraga. (2022) Molecular and cellular factors determining the functional pleiotropy of cytokines. The FEBS Journal 290:10, pages 2525-2552.
Crossref
Crossref
Haohao Lu, Qing Ye, Chuansheng Zheng, Li Fan & Xiangwen Xia. (2023) Efficacy and safety analysis of TACE + sunitinib vs. sunitinib in the treatment of unresectable advanced renal cell carcinoma: a retrospective study. BMC Cancer 23:1.
Crossref
Crossref
Romy Steiner & Nina Pilat. (2023) The potential for Treg-enhancing therapies in transplantation. Clinical and Experimental Immunology 211:2, pages 122-137.
Crossref
Crossref
Robert A. Saxton, Caleb R. Glassman & K. Christopher Garcia. (2022) Emerging principles of cytokine pharmacology and therapeutics. Nature Reviews Drug Discovery 22:1, pages 21-37.
Crossref
Crossref
William G. KaelinJr.Jr.. (2022) Von Hippel–Lindau disease: insights into oxygen sensing, protein degradation, and cancer. Journal of Clinical Investigation 132:18.
Crossref
Crossref
Merve Uslu, Esra Albayrak & Fatih Kocabaş. (2022) Competitive inhibition of IL-2/IL-2R has a dual effect on HSC ex vivo expansion and IL-2R (CD25) content. International Immunopharmacology 110, pages 109035.
Crossref
Crossref
Madhuri Sharon. 2022. Nanoparticles for Therapeutic Applications. Nanoparticles for Therapeutic Applications
209
275
.
Bulent Cetin, Chiara A. Wabl & Ozge Gumusay. (2022) Reshaping Treatment Paradigms for Advanced Renal Cell Cancer Patients and Improving Patient Management. Current Treatment Options in Oncology 23:4, pages 609-629.
Crossref
Crossref
Daria S. Chulpanova, Zarema E. Gilazieva, Sevindzh K. Kletukhina, Aleksandr M. Aimaletdinov, Ekaterina E. Garanina, Victoria James, Albert A. Rizvanov & Valeriya V. Solovyeva. (2021) Cytochalasin B-Induced Membrane Vesicles from Human Mesenchymal Stem Cells Overexpressing IL2 Are Able to Stimulate CD8+ T-Killers to Kill Human Triple Negative Breast Cancer Cells. Biology 10:2, pages 141.
Crossref
Crossref
Barbara Carreira, Rita C. Acúrcio, Ana I. Matos, Carina Peres, Sabina Pozzi, Daniella Vaskovich‐Koubi, Ron Kleiner, Mariana Bento, Ronit Satchi‐Fainaro & Helena F. Florindo. (2020) Nanomedicines as Multifunctional Modulators of Melanoma Immune Microenvironment. Advanced Therapeutics 4:1, pages 2000147.
Crossref
Crossref
Ghasem Rahimi Kalateh Shah Mohammad, Atefeh Ghahremanloo, Arash Soltani, Esmat Fathi & Seyed Isaac Hashemy. (2020) Cytokines as potential combination agents with PD‐1/PD‐L1 blockade for cancer treatment. Journal of Cellular Physiology 235:7-8, pages 5449-5460.
Crossref
Crossref
Daria S. Chulpanova, Valeriya V. Solovyeva, Victoria James, Svetlana S. Arkhipova, Marina O. Gomzikova, Ekaterina E. Garanina, Elvira R. Akhmetzyanova, Leysan G. Tazetdinova, Svetlana F. Khaiboullina & Albert A. Rizvanov. (2020) Human Mesenchymal Stem Cells Overexpressing Interleukin 2 Can Suppress Proliferation of Neuroblastoma Cells in Co-Culture and Activate Mononuclear Cells In Vitro. Bioengineering 7:2, pages 59.
Crossref
Crossref
Jared E Lopes, Jan L Fisher, Heather L Flick, Chunhua Wang, Lei Sun, Marc S Ernstoff, Juan C Alvarez & Heather C Losey. (2020) ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy. Journal for ImmunoTherapy of Cancer 8:1, pages e000673.
Crossref
Crossref
Maryam Tahvildari & Reza Dana. (2019) Low-Dose IL-2 Therapy in Transplantation, Autoimmunity, and Inflammatory Diseases. The Journal of Immunology 203:11, pages 2749-2755.
Crossref
Crossref
Lorenzo Mortara, Enrica Balza, Antonino Bruno, Alessandro Poggi, Paola Orecchia & Barbara Carnemolla. (2018) Anti-cancer Therapies Employing IL-2 Cytokine Tumor Targeting: Contribution of Innate, Adaptive and Immunosuppressive Cells in the Anti-tumor Efficacy. Frontiers in Immunology 9.
Crossref
Crossref
Xi Chen, Xiaojie Ai, Chunlian Wu, Heyong Wang, Gang Zeng, Peixin Yang & Gentao Liu. (2018) A novel human IL-2 mutein with minimal systemic toxicity exerts greater antitumor efficacy than wild-type IL-2. Cell Death & Disease 9:10.
Crossref
Crossref
. (2018) Retraction: Update on the Application of Interleukin-2 in the Treatment of Renal Cell Carcinoma. Clinical Cancer Research 24:15, pages 3783-3783.
Crossref
Crossref
Suman Mitra & Warren J Leonard. (2018) Biology of IL-2 and its therapeutic modulation: Mechanisms and strategies. Journal of Leukocyte Biology 103:4, pages 643-655.
Crossref
Crossref
Rakeeb Kureshi, Michelle Bahri & Jamie B Spangler. (2018) Reprogramming immune proteins as therapeutics using molecular engineering. Current Opinion in Chemical Engineering 19, pages 27-34.
Crossref
Crossref
Howard L. Kaufman, Michael B. Atkins, Adam P. Dicker, Heather S. Jim, Louis P. Garrison, Roy S. Herbst, William T. McGivney, Steven Silverstein, Jon M. Wigginton & Peter P. Yu. (2017) The Value of Cancer Immunotherapy Summit at the 2016 Society for Immunotherapy of Cancer 31st Anniversary Annual Meeting. Journal for ImmunoTherapy of Cancer 5:1.
Crossref
Crossref
Ziye Pan, Jinjiao He, Lubna M. Rasoul, Yunye Liu, Ruixiang Che, Yun Ding, Xiaocheng Guo, Jiarui Yang, Dehua Zou, Hua Zhang, Deshan Li & Hongwei Cao. (2016) Identification of Optimal Insertion Site in Recombinant Newcastle Disease Virus (rNDV) Vector Expressing Foreign Gene to Enhance Its Anti-Tumor Effect. PLOS ONE 11:10, pages e0164723.
Crossref
Crossref
Guiping Ren, Guiyou Tian, Yunye Liu, Jinjiao He, Xinyu Gao, Yinhang Yu, Xin Liu, Xu Zhang, Tian Sun, Shuangqing Liu, Jiechao Yin & Deshan Li. (2016) Recombinant Newcastle Disease Virus Encoding IL-12 and/or IL-2 as Potential Candidate for Hepatoma Carcinoma Therapy. Technology in Cancer Research & Treatment 15:5, pages NP83-NP94.
Crossref
Crossref
Ninh M. La-Beck, Gary W. Jean, Cindy Huynh, Saeed K. Alzghari & Devin B. Lowe. (2015) Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 35:10, pages 963-976.
Crossref
Crossref
Jamie B. SpanglerIgnacio MoragaJuan L. MendozaK. Christopher Garcia. (2015) Insights into Cytokine–Receptor Interactions from Cytokine Engineering. Annual Review of Immunology 33:1, pages 139-167.
Crossref
Crossref
C. Lance Cowey & Thomas E. Hutson. 2015. Renal Cell Carcinoma. Renal Cell Carcinoma
349
375
.
Rodney A Rosalia, Natalia Arenas-Ramirez, Grégory Bouchaud, Miro E Raeber & Onur Boyman. (2014) Use of enhanced interleukin-2 formulations for improved immunotherapy against cancer. Current Opinion in Chemical Biology 23, pages 39-46.
Crossref
Crossref
Petra Votavova, Jakub Tomala & Marek Kovar. (2014) Increasing the biological activity of IL-2 and IL-15 through complexing with anti-IL-2 mAbs and IL-15Rα-Fc chimera. Immunology Letters 159:1-2, pages 1-10.
Crossref
Crossref
Julien Laurent, Cedric Touvrey, Silke Gillessen, Magali Joffraud, Manuela Vicari, Caroline Bertrand, Stefano Ongarello, Bernd Liedert, Elisa Gallerani, Joachim Beck, Aurelius Omlin, Cristiana Sessa, Sonia Quaratino, Roger Stupp, Ulrike S Gnad-Vogt & Daniel E Speiser. (2013) T-cell activation by treatment of cancer patients with EMD 521873 (Selectikine), an IL-2/anti-DNA fusion protein. Journal of Translational Medicine 11:1.
Crossref
Crossref
S. Wang, H. T. Li, Y. H. Liu, Y. Z. Zhu, W. H. Wang, Y. X. An & L. G. Miao. (2013) Expression, Identification and Characterize of CD25-Binding Epitope Modified Human IL-2 in Pichia pastoris. Indian Journal of Microbiology 53:3, pages 283-287.
Crossref
Crossref
Ramon Arens, Thorbald van Hall, Sjoerd H. van der Burg, Ferry Ossendorp & Cornelis J.M. Melief. (2013) Prospects of combinatorial synthetic peptide vaccine-based immunotherapy against cancer. Seminars in Immunology 25:2, pages 182-190.
Crossref
Crossref
O. Boyman, C. Krieg, S. Letourneau, K. Webster, C.D. Surh & J. Sprent. (2012) Selectively Expanding Subsets of T Cells in Mice by Injection of Interleukin-2/Antibody Complexes: Implications for Transplantation Tolerance. Transplantation Proceedings 44:4, pages 1032-1034.
Crossref
Crossref
Onur Boyman & Jonathan Sprent. (2012) The role of interleukin-2 during homeostasis and activation of the immune system. Nature Reviews Immunology 12:3, pages 180-190.
Crossref
Crossref
Suzanne L. TopalianGeorge J. WeinerDrew M. Pardoll. (2011) Cancer Immunotherapy Comes of Age. Journal of Clinical Oncology 29:36, pages 4828-4836.
Crossref
Crossref
Masaki Mandai, Noriomi Matsumura, Tsukasa Baba, Ken Yamaguchi, Junzo Hamanishi & Ikuo Konishi. (2011) Ovarian clear cell carcinoma as a stress-responsive cancer: Influence of the microenvironment on the carcinogenesis and cancer phenotype. Cancer Letters 310:2, pages 129-133.
Crossref
Crossref
Cheng-yao WU, Zhen-sheng ZHANG, Chuan-liang XU, Yang WANG, Qin-song ZENG, Wei-dong XU, Tai-le JING, Dan SHEN, Jian SHEN, Fu-bo WANG & Ying-hao SUN. (2011) Diagnosis and treatment of gastric metastasis of clear cell renal cell carcinoma: a case report and review of literatures. Academic Journal of Second Military Medical University 31:5, pages 575-577.
Crossref
Crossref
Courtney Nicholas & Gregory B Lesinski. (2011) Immunomodulatory cytokines as therapeutic agents for melanoma. Immunotherapy 3:5, pages 673-690.
Crossref
Crossref
Carsten Krieg, Sven Létourneau, Giuseppe Pantaleo & Onur Boyman. (2010) Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells. Proceedings of the National Academy of Sciences 107:26, pages 11906-11911.
Crossref
Crossref
Michele Basso, Alessandra Cassano & Carlo Barone. (2010) A survey of therapy for advanced renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations 28:2, pages 121-133.
Crossref
Crossref
Michael Staehler, Nico Haseke, Ekaterina Zilinberg, Thomas Stadler, Alexander Karl, Michael Siebels, Hans-Roland Dürr, Sabine Siegert, Karl W. Jauch, Christiane J. Bruns & Christian G. Stief. (2010) Complete remission achieved with angiogenic therapy in metastatic renal cell carcinoma including surgical intervention. Urologic Oncology: Seminars and Original Investigations 28:2, pages 139-144.
Crossref
Crossref
Eva Juengel, Johanna Engler, Iyad Natsheh, Jon Jones, Ausra Mickuckyte, Lukasz Hudak, Dietger Jonas & Roman A Blaheta. (2009) Combining the receptor tyrosine kinase inhibitor AEE788 and the mammalian target of rapamycin (mTOR) inhibitor RAD001 strongly inhibits adhesion and growth of renal cell carcinoma cells. BMC Cancer 9:1.
Crossref
Crossref
Jon Jones, Eva Juengel, Ausra Mickuckyte, Lukasz Hudak, Steffen Wedel, Dietger Jonas, Gudrun Hintereder & Roman A. Blaheta. (2008) Valproic acid blocks adhesion of renal cell carcinoma cells to endothelium and extracellular matrix. Journal of Cellular and Molecular Medicine 13:8b, pages 2342-2352.
Crossref
Crossref
Marianna SabatinoSeunghee Kim-SchulzeMonica C. PanelliDavid StroncekEna WangBret TabackDae Won KimGail DeRaffeleZoltan PosFrancesco M. MarincolaHoward L. Kaufman. (2009) Serum Vascular Endothelial Growth Factor and Fibronectin Predict Clinical Response to High-Dose Interleukin-2 Therapy. Journal of Clinical Oncology 27:16, pages 2645-2652.
Crossref
Crossref
Patrick Schöffski, Vincente Guillem, Margarita Garcia, Fernando Rivera, Josep Tabernero, Martin Cullell, Jose Antonio Lopez-Martin, Patricia Pollard, Herlinde Dumez, Xavier Garcia del Muro & Luis Paz-Ares. (2009) Phase II Randomized Study of Plitidepsin (Aplidin), Alone or in Association with L-carnitine, in Patients with Unresectable Advanced Renal Cell Carcinoma. Marine Drugs 7:1, pages 57-70.
Crossref
Crossref
J. C. Oosterwijk-Wakka, Otto C. Boerman, Peter F. A. Mulders & Egbert Oosterwijk. 2009. Renal Cell Carcinoma. Renal Cell Carcinoma
231
247
.
Alonso V. Pacheco, Kanwaldeep Rasila, Sang-Joon Lee, Ian Rabinowitz, Laurence Elias, Fa Chyi Lee & Claire F. Verschraegen. (2008) Phase II studies of antiangiogenic four drug regimens for the treatment of advanced renal cell carcinoma: FUNIL-retinoid and the FUNIL-thalidomide protocols. Urologic Oncology: Seminars and Original Investigations 26:6, pages 610-615.
Crossref
Crossref
William H.D. Hallett, Erik Ames, Maite Álvarez, Isabel Barao, Patricia A. Taylor, Bruce R. Blazar & William J. Murphy. (2008) Combination Therapy Using IL-2 and Anti-CD25 Results in Augmented Natural Killer Cell–Mediated Antitumor Responses. Biology of Blood and Marrow Transplantation 14:10, pages 1088-1099.
Crossref
Crossref
Robert J. Amato, Jaroslaw Jac & Joan Hernandez-McClain. (2008) Interferon-α in combination with either imatinib (Gleevec) or gefitinib (Iressa) in metastatic renal cell carcinoma: a phase II trial. Anti-Cancer Drugs 19:5, pages 527-533.
Crossref
Crossref
Minoru Kobayashi, Hitoshi Ikeda, Akinori Nukui, Kazumi Suzuki, Yasuhiro Sugaya, Masayuki Yuzawa & Tatsuo Morita. (2008) Clinical outcome and prognostic survival factors in patients with advanced renal cell carcinoma treated with very low-dose interleukin-2, interferon-α, and tegafur-uracil: a single-institution experience. International Journal of Clinical Oncology 13:3, pages 257-262.
Crossref
Crossref
Juliana Hamzah, Delia Nelson, Gerd Moldenhauer, Bernd Arnold, Günter J. Hämmerling & Ruth Ganss. (2008) Vascular targeting of anti-CD40 antibodies and IL-2 into autochthonous tumors enhances immunotherapy in mice. Journal of Clinical Investigation 118:5, pages 1691-1699.
Crossref
Crossref
Mustapha Allam, Nathalie Julien, Boulos Zacharie, Christopher Penney & Lyne Gagnon. (2007) Enhancement of Th1 type cytokine production and primary T cell activation by PBI-1393. Clinical Immunology 125:3, pages 318-327.
Crossref
Crossref
O. Takikawa. (2007) Clinical aspects of indoleamine 2,3-dioxygenase (IDO)-initiated tryptophan metabolism: IDO is a target of drug discovery for various diseases. International Congress Series 1304, pages 290-297.
Crossref
Crossref
Robert J. Amato. (2007) Current Immunotherapeutic Strategies in Renal Cell Carcinoma. Surgical Oncology Clinics of North America 16:4, pages 975-986.
Crossref
Crossref
Chie Kudo-Saito, Elizabeth K. Wansley, M. Eilene Gruys, Robert Wiltrout, Jeffrey Schlom & James W. Hodge. (2007) Combination Therapy of an Orthotopic Renal Cell Carcinoma Model Using Intratumoral Vector-Mediated Costimulation and Systemic Interleukin-2. Clinical Cancer Research 13:6, pages 1936-1946.
Crossref
Crossref
Chong Wing Yung, Timothy A. Barbari & William E. Bentley. (2006) Integrated non‐invasive system for quantifying secreted human therapeutic hIL2. Biotechnology and Bioengineering 95:5, pages 938-945.
Crossref
Crossref
Robert Dreicer. (2006) Tyrosine Kinase Inhibitors Compared with Cytokine Therapy for Metastatic Renal Cell Carcinoma: Overview of Recent Clinical Trials Differentiating Clinical Response and Adverse Effects. Clinical Genitourinary Cancer 5, pages S19-S23.
Crossref
Crossref
Kimberly A. Varker, Sri Vidya Kondadasula, Michael R. Go, Gregory B. Lesinski, Rupa Ghosh-Berkebile, Amy Lehman, J. Paul Monk, Thomas Olencki, Kari Kendra & William E. CarsonIIIIII. (2006)
Multiparametric Flow Cytometric Analysis of Signal Transducer and Activator of Transcription 5 Phosphorylation in Immune Cell Subsets
In vitro
and following Interleukin-2 Immunotherapy
. Clinical Cancer Research 12:19, pages 5850-5858.
Crossref
Crossref
Johan Robbens, Wim De Coen, Walter Fiers & Erik Remaut. (2006) Improved periplasmic production of biologically active murine interleukin-2 in Escherichia coli through a single amino acid change at the cleavage site. Process Biochemistry 41:6, pages 1343-1346.
Crossref
Crossref
Francesco M. Boccardo, Pamela Guglielmini & Laura Tacchini. (2006) Medical Treatment of Advanced Renal Cell Carcinoma: Present Options and Future Directions. European Urology Supplements 5:8, pages 619-626.
Crossref
Crossref
Thomas E. Hutson & Ronald M. Bukowski. (2006) A Phase II Study of GW786034 Using a Randomized Discontinuation Design in Patients with Locally Recurrent or Metastatic Clear-Cell Renal Cell Carcinoma. Clinical Genitourinary Cancer 4:4, pages 296-298.
Crossref
Crossref
M. Staehler, N. Haseke, G. Schöppler, T. Stadler, C. Adam & C. G. Stief. (2006) Therapiestrategien des fortgeschrittenen NierenkarzinomsTherapy strategies for advanced renal cell carcinoma. Der Urologe 45:1, pages 99-112.
Crossref
Crossref
Osamu Takikawa. (2005) Biochemical and medical aspects of the indoleamine 2,3-dioxygenase-initiated l-tryptophan metabolism. Biochemical and Biophysical Research Communications 338:1, pages 12-19.
Crossref
Crossref
Lydia Koulova, Yelena Novik, Geralyn Caliendo, Peter Wiernik & Janice Dutcher. (2005) A Phase 2 Study of Moderate Dose Interleukin-2 and Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Metastatic or Unresectable Renal Cell Carcinoma. Journal of Immunotherapy 28:6, pages 576-581.
Crossref
Crossref
Robert J. Kreitman, David R. Squires, Maryalice Stetler-Stevenson, Pierre Noel, David J.P. FitzGerald, Wyndham H. Wilson & Ira Pastan. (2005) Phase I Trial of Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) in Patients With B-Cell Malignancies. Journal of Clinical Oncology 23:27, pages 6719-6729.
Crossref
Crossref
Michael Atkins, Meredith Regan, David McDermott, James Mier, Eric Stanbridge, Amanda Youmans, Philip Febbo, Melissa Upton, Mirna Lechpammer & Sabina Signoretti. (2005) Carbonic Anhydrase IX Expression Predicts Outcome of Interleukin 2 Therapy for Renal Cancer. Clinical Cancer Research 11:10, pages 3714-3721.
Crossref
Crossref
Michael B. Atkins. (2005) Management of advanced renal cancer. Kidney International 67:5, pages 2069-2082.
Crossref
Crossref
David F Stroncek, Christine Burns, Brian M Martin, Leonardo Rossi, Francesco M Marincola & Monica C Panelli. (2005) Advancing Cancer Biotherapy with Proteomics. Journal of Immunotherapy 28:3, pages 183-192.
Crossref
Crossref
Michael B. Atkins, Meredith Regan & David McDermott. (2004) Update on the Role of Interleukin 2 and Other Cytokines in the Treatment of Patients with Stage IV Renal Carcinoma. Clinical Cancer Research 10:18, pages 6342S-6346S.
Crossref
Crossref
Merve Uslu, Esra Albayrak & Fatih Kocabas. (2022) Competitive Inhibition of IL-2/IL-2R Has a Dual Effect on HSC Ex Vivo Expansion and IL-2R (CD25) Content. SSRN Electronic Journal.
Crossref
Crossref